Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Fiche publication
Date publication
décembre 2021
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Januel E, De Seze J, Vermersch P, Maillart E, Bourre B, Pique J, Moisset X, Bensa C, Maarouf A, Pelletier J, Vukusic S, Audoin B, Louapre C
Lien Pubmed
Résumé
Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry.
Mots clés
COVID-19, COVID-19 vaccine, anti-CD20 therapies, multiple sclerosis, neuromyelitis optica (NMO)
Référence
Mult Scler. 2021 Dec 21;:13524585211049737